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Axel Le Cesne2 and Jean-Yves Blay4*Abstract: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours
(GIST) receiving imatinib : an active agent only in non progressive patients.
Background: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is
frequently observed in patients with advanced GIST, and is one of the most frequent side effects of imatinib with
grade 3–4 anaemia in 10% of patients. Whether EPO treatment is useful in the management of GIST patients
receiving imatinib treatment is unknown.
Methods: A retrospective study of EPO treatment in GIST patients receiving imatinib was undertaken in 4 centres.
Thirty four patients received EPO treatment among the 319 GIST patients treated with imatinib in clinical trials or
with compassionate use between 2001 and 2003. The efficacy of EPO on the anaemia of patients with GIST treated
with imatinib was analyzed.
Results: There were 18 males and 16 females with a median age of 59 years. Median WHO-PS was 1. Primary
tumour sites were mainly gastric (32%) and small bowel (29%). Sites of metastases were mainly liver (82%) and
peritoneum (79%). The median delay between the initiation of imatinib treatment and EPO was 58 days (range 0–
553). Median haemoglobin (Hb) level prior to EPO was 9 g/dL (range 6,9-11,8) and 11,7 g/dL (range 6,8-14,4) after
2 months. An increase of more than 2 g/dL was observed in 18 (53%) of patients. None of the 7 patients who
progressed (PD) under imatinib treatment (400 mg/day) experienced HB response, as compared to 66% (18/27) of
the remaining patients (PR + SD) (p = 0,002). Primary tumour site, liver metastases, peritoneal metastases, age,
gender did not correlate with HB response to EPO. Response to EPO was observed in 2/11 patients receiving
high-dose imatinib (800 mg/day) vs 16/23 of others. Using logistic regression, only PD before EPO treatment
was retained as a predictive factor for EPO response.
Conclusion: EPO enables to increase Hb in most anaemic GIST patients who do not progress under imatinib,
but not in patients with progressive disease.
Keywords: GIST, Imatinib, Anaemia* Correspondence: jean-yves.blay@lyon.unicancer.fr
4Centre Léon Bérard, Department of Medecine, French Sarcoma Group
(GSF-GETO), European Organisation for Research and Treatment of Cancer
(EORTC), University Claude Bernard Lyon I, Lyon, France
Full list of author information is available at the end of the article
© 2012 Duffaud et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Duffaud et al. Clinical Sarcoma Research 2012, 2:11 Page 2 of 5
http://www.clinicalsarcomaresearch.com/content/2/1/11Introduction
Imatinib (GlivecW / GleevecW, Novartis) is an orally admi-
nistered small molecule tyrosine kinase inhibitor active
against BCR-ABL, KIT, and PDGF. It has proven to be
remarkably effective in gastrointestinal stromal tumours
(GIST) patients with advanced/metastatic disease [1-5], as
well as in adjuvant phase [6]. Imatinib is approved world-
wide for use in GIST, with a usual recommended dose of
400 mg daily [7]. Overall, imatinib is well tolerated, but
severe side effects are reported in 2-5% of patients [8].
Anaemia is one of the most frequent side effects observed
in imatinib treated patients with GIST (90% of patients),
mostly mild to moderate, while this drug is associated with
severe grade 3–4 anaemia in less than 10% of patients [8].
Erythropoietin (EPO) is well demonstrated to improve
anaemia associated with chemotherapy in solid tumours
and quality of life in anaemic patients with cancer [9]. It
reduces the need of red blood cell transfusion in cancer
patients. Whether EPO treatment is useful in the manage-
ment of GIST patients receiving imatinib is unknown.
In the present retrospective study, the impact of EPO
treatment on the symptomatic anaemia of GIST patients




This retrospective study of EPO treatment in GIST
patients receiving imatinib was performed in 4 French
centers (Institut Gustave Roussy, Villejuif, Hôpital E.
Hérriot, Lyon, Centre Léon Bérard, Lyon, Hôpital La
Timone, Marseille). Patients with histologically proven
advanced unresectable and/or metastatic GIST charac-
terized by KIT expression (assessed by DAKO assay
based on immunohistochemistry), receiving imatinib
(GlivecW) in clinical trials or with compassionate use,
and who developed anaemia (haemoglobin ≤ 11 g/dL)
were treated with EPO. All patients had measurable
disease as defined by Response Evaluation Criteria in
Solid Tumours (RECIST).
Treatment plan and dose modifications
Patients were treated for anaemia with weekly doses of
30,000U EPO subcutaneously (epoetin alpha, n= 30, 88%
or epoietin beta, n = 2, 6%) or 150 μg/week of darbepoetin
alpha (n= 2, 6%) until the haemoglobin (Hb) level increase
up to 11–13 g/dL according to the recommendations for
clinical use. EPO was discontinued if the Hb levels
remained stable at 11–13 g/dL or higher. For patients with
suspected iron-deficient anaemia (based on clinical history
and red blood cell parameters), levels of serum iron, iron-
binding capacity, and serum ferritin were evaluated, as
was any possible cause of blood loss, before EPO was
considered. Only patients with iron-deficient anaemiareceived iron supplementation. Serum EPO levels were
not screened before the initiation of EPO therapy.
For the purpose of the current analysis, a favourable
response to EPO was considered as a sustained (i.e.
lasting > 4 weeks) increase in the Hb level≥ 2 g/dL from
the pre-treatment values. Dose reductions of imatinib for
non haematological or haematological toxic effects were
initiated according to the clinical trials recommendations
[3-5]. No dose interruptions or dose reductions were indi-
cated for anaemia alone. Patients were followed with
complete blood counts (CBC) weekly during the first
4 weeks of imatinib therapy and then every 2–4 weeks.
Statistical considerations
A univariate analysis was performed on the following
variables: age at diagnosis, sex, site of metastases, initial
dose of imatinib, and response to imatinib. Statistical
significance was determined using the Fisher exact test.
To identify the potential predictive factors of EPO
efficacy, a logistic regression model was performed.
Results
Thirty four patients who developed anaemia (Hb level
≤ 11 g/dL) among the 319 (11%) GIST patients treated
with imatinib in clinical trials or with compassionate use
in the 4 French centres, between July 2001 and August
2003, received EPO therapy. The median time from the
initiation of imatinib to the initiation of EPO was 58 days
(range, 0–553 days). 2 patients started imatinib and Epo
on the same day. Demographic and clinical characteristics
are presented in Table 1. There were 18 males and 16
females with a median age of 59 years (range, 29–85 years)
and a median WHO-PS of 1 (range, 0–3). Thirty two
patients had a metastatic GIST and two patients had a
locally advanced disease. The primary tumour sites were
gastric (n= 11, 32%) and small bowel (n= 10, 29%). Of
note, a relative large proportion of patients had primary
mesenteric or peritoneal GIST (10, 30%). The sites of
metastases were mainly liver (82%) and peritoneum (79%).
Ten out of 34 (29%) patients required red blood transfusion
before starting EPO treatment.
Response to the EPO treatment is presented in Table 2.
Median Hb level prior to EPO was 9 g/dL (range, 6.9-
11.8 g/dL) and 11.7 g/dL (range, 6.8-14.4 g/dL) after
2 months. Of the 34 patients receiving EPO, 18 (53%)
had an increase in Hb levels of ≥ 2 g/dL. Eight additional
patients had an increase in Hb levels of 1–1.9 g/dL.
Therefore, only 8 of 34 (23.5%) patients had no response
at all to EPO therapy. None of the 7 patients who had
previously progressed (PD) under imatinib (400 mg/day)
obtained an Hb increase after EPO treatment, as
compared to 66% (18/27) of the remaining patients
(patients with a partial response to imatinib or with
a disease stabilization, \PR + SD]) (p = 0,002). There














Small Intestine 10 (29.4%)
Mesentery 7 (20.6%)
Other 6 (17.6%)






Transfusion before EPO treatment
Yes 10 (29%)/
No 24 (71%)
Starting Dose of Imatinib/day
400 mg 25(67.6%)
800 mg 9(11.7%)
Table 2 Haemoglobin response and clinical parameters
Clinical paramaters Response to EPO, N(%) Chi square
Non Response Response P value
Response to Glivec
SD+PR 9(56.3%) 18(100%) 0.02
PD 7(44%) 0(0%)
Male 9(56.3%) 9(50%) 0.7
Female 7(44%) 9(50%)
Liver metastases
No 1(6.3%) 5(28%) 0.2
Yes 15(94%) 13(72%)
Lung metastases
No 14(875%) 16(89%) 1.0
Yes 2(12.5%) 2(11%)
Peritoneal metastases
No 3(19%) 6(33.5%) 0.44
Yes 13(81.5%) 12(66.5%)
Imatinib dose
400 mg/d 9(56.3%) 16(89%) 0.05
800 mg/d 7(44%) 2(11%)
Age
≥ 60 years 8(50%) 9(50%) 1.0
< 60 years 8(50%) 9(50%)
° Ficher exact test.
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binant EPO used, but there were only 2 patients treated
with Epo beta, and darbepoietin respectively. No patient
discontinued imatinib therapy because of anaemia. Six non-
responding patients to EPO required red blood cells
transfusion.
An important question is whether EPO administration
is active on the anaemia induced by imatinib, on the
anaemia induced by the tumor through iron loss or in-
flammation, or both. The efficacy of EPO in patients who
initiated EPO treatment within the first 2 months of
imatinib initiation, between 2 and 6 months and beyond
was compared: no significant difference was observed
between the three groups (p= 0,3, not shown), indicating
that EPO is active also in patients who develop anaemia as
a consequence of imatinib treatment,
Primary tumour site, liver and peritoneal metastases,
age and gender did not correlate with Hb response toEPO. Response to EPO was observed in 2/9 (22%)
patients receiving high-dose imatinib as initial treatment
(800 mg/day) versus 16/25 (64%) of others (p= 0.05).
Using logistic regression analysis, disease progression (PD)
before EPO treatment was the only parameter retained as
a predictive factor for EPO response.Discussion
Anaemia is a frequently reported haematological side
effect in clinical trials with imatinib in GIST [1-4].
To our knowledge, the capacity of EPO to improve the
anaemia observed in patients treated with imatinib in
GISTs has not been reported, and no article has been
reported on this topic within Pubmed (date of access
25/3/2012).
In this study, we investigated the efficacy of EPO
treatment on the anaemia of GIST patients treated
with imatinib and the predictive factors of EPO efficacy.
Hb levels increased in 76.5% of patients following EPO
administration in this retrospective study. Of note, some-
patients were given EPO with baseline Hb levels above
11 g/dL. This reflects practices which are no longer
recommended following the recent clinical practice guide-
lines regarding EPO administration in cancer patients
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retrospective study, and no severe complications possibly
caused by imatinib were reported.
Surprisingly, an over representation of mesenteric GIST
is observed in this relatively small series of patients, possibly
because of a more aggressive behaviour of primary tumors
occurring in these sites, resulting in a greater impact on the
general status of the patient.
It has been reported that EPO improves anaemia induced
by imatinib therapy in patients with chronic myeloid
leukaemia in chronic phase [11]. The present data
confirm that EPO is also an efficient treatment in
patients with GIST. However, only patients in whom
imatinib induces tumor control were found to respond
to EPO, and none of the patients progressing under
imatinib achieved Hb response to EPO. Importantly,
baseline Epo levels were not measured in this series.
The role of the paraneoplastic inflammatory syndrome
in the resistance to EPO in progressive patients was not
investigated either. The impact of iron supplementation
in non sideropenic patients, while controversial, was
also not explored in this retrospective series, but may
also be worth exploring in refractory patients.
For symptomatic and persistent anaemia associated with
imatinib, EPO may therefore be considered. Further studies
investigating the impact on other measures, such as quality
of life and fatigue are needed to measure the benefits of this
treatment, even though. Furthermore, the 62005 intergroup
phase III trial from EORTC-STBSG [12] in advanced/
metastatic GIST patients reported that Hb level is sig-
nificantly correlated to imatinib response and to pro-
gression free survival (PFS) with high imatinib response
and favourable PFS predicted by high Hb level. Whether
EPO treatment improves imatinib antitumour activity in
this context remains to be explored. It must be stressed
however that EPO treatment has been reported to impact
negatively on survival in a meta-analysis of all Epo trials
[10]. The present retrospective study is of course not ad-
equate to address this important question.
It can be concluded that Epo treatment increases Hb
level in patients with GIST receiving imatinib with anaemia,
whether related to imatinib treatment or to the disease, but
that this benefits only to patients achieving tumour control
under imatinib treatment.Competing interest
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